TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23307042
Drug: LAS group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAS group: LPZ 30 mg twice a day + AMPC 750 mg twice a day + sitafloxacin (STFX) 100 mg twice a day for one week
Study: 7691775
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser treatment
Study: 22610178
Drug: Fluid-conservative therapy
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid-conservative therapy
Study: 22610178
Drug: Fluid-liberal therapy
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid-liberal therapy
Study: 20565154
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with frequent urine toxicology monitoring
Study: 18460957
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of QR-CRP, absolute neutrophil count, and white blood cell count
Study: 11772270
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple therapy monocapsule (Helicide) containing bismuth, tetracycline, and metronidazole.
Study: 11772270
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple therapy (without the monocapsule) including bismuth, tetracycline, and metronidazole.
Study: 16381993
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment for 9 months
Study: 10799368
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) 50:0 g
Study: 10799368
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) 40:10 g
Study: 10799368
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) 30:20 g
Study: 10799368
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) 20:30 g
Study: 10799368
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (casein 0:50 g)
Study: 10799368
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) 30 g
Study: 10799368
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) 40 g
Study: 8970834
Drug: Bioartificial liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioartificial liver (BAL) treatment for FHF patients
Study: 8970834
Drug: Bioartificial liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioartificial liver (BAL) treatment for chronic liver failure patients
Study: 1568544
Drug: Effervescent citrate-cimetidine
Normalized name: cimetidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent citrate-cimetidine combination (200 mg cimetidine/tablet)
Study: 1568544
Drug: Liquid aluminium-magnesium
Normalized name: Aluminium magnesium silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid aluminium-magnesium hydroxide antacid
Study: 29931231
Drug: Synbiotic yogurt
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic yogurt (300 g daily containing 108 colony-forming units Bifidobacterium animalis/mL and 1.5 g inulin)
Study: 29931231
Drug: Conventional yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yogurt (daily)
Study: 27803925
Drug: VAWI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAWI treatment (group B)
Study: 27803925
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (group A)
Study: 20537164
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg flat dose, subcutaneously)
Study: 11830196
Drug: Direct thrombin
Normalized name: Direct thrombin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct thrombin inhibitors (hirudin, bivalirudin, argatroban, efegatran, or inogatran)
Study: 7781397
Drug: Chemotherapy, magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, magnetic resonance imaging, endoesophageal ultrasound, and/or surgical staging
Study: 3728269
Drug: Mexiletine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine treatment
Study: 31196501
Drug: Elental® (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elental® (treatment group)
Study: 27633965
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus erlotinib (arm B)
Study: 17463072
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (IFN beta-1a) therapy
Study: 15927922
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg daily for 3 months)
Study: 15927922
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (150 microg/ml incubation)
Study: 10960463
Drug: PEG‐Intron 0.35,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐Intron 0.35, 0.7, or 1.4 microg/kg subcutaneously weekly for 24 weeks plus ribavirin 600, 800, or 1,000 to 1,200 mg orally daily.
Study: 10960463
Drug: PEG‐Intron alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐Intron alone (0.35, 0.7, or 1.4 microg/kg subcutaneously weekly for 24 weeks).
Study: 31590438
Drug: Fibre supplementation
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplementation (twice-a-day for 2 years)
Study: 29122463
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of TDV 3 months apart (group 1)
Study: 29122463
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of TDV (group 2)
Study: 29122463
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of TDV and a booster dose 1 year later (group 3)
Study: 29122463
Drug: Vaccine-related unsolicited
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-related unsolicited adverse events
Study: 27575577
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at GV 26, Ex‐HN 3, bilateral LI 4, and ST 36 for 10 minutes
Study: 11918762
Drug: nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nandrolone decanoate (ND; 200 mg/week IM)
Study: 1851824
Drug: 5.0‐g sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0‐g sodium alginate supplement (algae‐isolate, 75% soluble fiber)
Study: 26942320
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist ropinirole 0.5 mg
Study: 26942320
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist ropinirole 1.0 mg
Study: 24781725
Drug: Levosimendan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12.5 mg, 0.1 µg kg(‐1) per min; n = 17)
Study: 21975558
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate 2 mg bimonthly
Study: 21975558
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate 3 mg quarterly
Study: 21975558
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate (previously treated with daily oral ibandronate or placebo IV)
Study: 20499255
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg nafamostat mesilate diluted in a 5% glucose solution
Study: 20499255
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml 5% glucose solution (Control)
Study: 19734185
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg/day
Study: 18065333
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg/day
Study: 10662480
Drug: CIP/MTZ i.v./PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIP/MTZ i.v./PO (ciprofloxacin plus metronidazole, intravenous to oral)
Study: 10662480
Drug: CIP/MTZ i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIP/MTZ i.v. or IMI i.v. (ciprofloxacin plus metronidazole intravenous or imipenem-cilastatin intravenous)
Study: 10662480
Drug: IMI i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMI i.v. (imipenem-cilastatin intravenous)
Study: 10662480
Drug: CIP/MTZ i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIP/MTZ i.v. (ciprofloxacin plus metronidazole intravenous)
Study: 7779645
Drug: Clotrimazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (500 mg pessary and 1% cream)
Study: 7779645
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg bd oral dose for 1 day)
Study: 2539186
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg single oral dose)
Study: 2178597
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (various doses)
Study: 31404106
Drug: MNS autoantibody
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNS autoantibody assay (combination of four autoantibodies and free/total PSA ratio)
Study: 12854478
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of fentanyl (1 microgram.kg‐1 before operation and 0.02 microgram.kg‐1.min‐1 during operation) and propofol (4‐10 mg.kg‐1.min‐1)
Study: 10372614
Drug: Gastric feeds
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric feeds (G)
Study: 1806034
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 250 mg as a single i.v. injection before chemotherapy
Study: 6957992
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose pirenzepine therapy (100 mg/day) for 28 days
Study: 6957992
Drug: Low pirenzepine
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pirenzepine doses (50 mg/day) for 6 months
Study: 6957992
Drug: Pirenzepine withdrawal
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine withdrawal (no treatment)
Study: 6957992
Drug: Antacid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid therapy (28 days) followed by withdrawal
Study: 30383298
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) + Surgical Treatment (ST)
Study: 30383298
Drug: Surgical Treatment
Normalized name: SURGICAL AIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Treatment (ST) only
Study: 22846413
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg 3 times daily and vitamin E 400 IU daily for 6 months
Study: 21701421
Drug: Eritoran 45
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran 45 mg/105 mg
Study: 15590252
Drug: Remifentanil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.01 mg
Study: 18081358
Drug: Sufentanil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.01 mg
Study: 12801256
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (control)
Study: 11450490
Drug: Preoperative macular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative macular laser treatment
Study: 8185877
Drug: Transdermal physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal physostigmine
Study: 2967625
Drug: Sublingual NIF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual NIF (10 mg)
Study: 31954959
Drug: Cognitive-behavioral-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral-based physical therapy (CBPT-ACLR) intervention
Study: 29908420
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose followed by 90 mg twice daily maintenance dose
Study: 29908420
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose followed by 75 mg/day maintenance dose
Study: 27866517
Drug: Systematic, integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic, integrated and highly‐intensive pulmonary rehabilitation for 7 days including pharmacotherapy and physical rehabilitation
Study: 23327958
Drug: ω‐3 fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 fish oil lipid emulsion (0.2 g×kg(‐1)×d(‐1), 10%) for 14 days
Study: 20679143
Drug: NVP 0
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 0 g
Study: 20679143
Drug: NVP 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP 2.5 g
Study: 20679143
Drug: NVP 5
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 5 g
Study: 20679143
Drug: NVP 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP 7.5 g
Study: 18836346
Drug: Ropinirole 0.5
Normalized name: ropinirole 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole 0.5 to 6.0 mg/d twice daily
Study: 16671257
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine (15 microg x Kg(‐1))
Study: 16671257
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.3 mg x Kg(‐1))
Study: 9196161
Drug: M-VAC as
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-VAC as second-line therapy after gallium nitrate/5-FU
Study: 3539028
Drug: Inositol (120-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (120-160 mg/kg/day) administered by the ingastric or intravenous route
Study: 27928815
Drug: 20 mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/daily tadalafil
Study: 27928815
Drug: 0.4 mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/daily tamsulosin
Study: 27928815
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.4 mg/daily tamsulosin and 20 mg/daily tadalafil
Study: 17334518
Drug: Low-dose ZK-807834
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ZK-807834
Study: 17334518
Drug: Medium-dose ZK-807834
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ZK-807834
Study: 17334518
Drug: High-dose ZK-807834
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ZK-807834
Study: 11251005
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (2.3 mg/m²/day for 5 days, every 21 days)
Study: 11251005
Drug: IV topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV topotecan (1.5 mg/m²/day for 5 days, every 21 days)
Study: 9556142
Drug: Intravenous olpadronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous olpadronate 4 mg daily for 5 days
Study: 9556142
Drug: Oral olpadronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral olpadronate 200 mg daily after initial intravenous treatment
Study: 9556142
Drug: Intravenous olpadronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous olpadronate only (no oral maintenance)
Study: 51964
Drug: 5-day cyclical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day cyclical combination chemotherapy
Study: 51964
Drug: 2-day cyclical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day cyclical combination chemotherapy
Study: 51964
Drug: 1-day cyclical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day cyclical combination chemotherapy
Study: 30595477
Drug: Tocilizumab (IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (IL-6 receptor antibody) during a 12-week intervention with bicycle exercise
Study: 30595477
Drug: Tocilizumab (IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (IL-6 receptor antibody) with no exercise
Study: 26921473
Drug: I-Gel
Normalized name: Di-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-Gel
Study: 22291076
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose chemotherapy (VIP + 3 cycles of high-dose carboplatin and etoposide)
Study: 22291076
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose chemotherapy (3 cycles of VIP + 1 cycle of high-dose carboplatin, etoposide, and cyclophosphamide)
Study: 12187294
Drug: Low cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cholesterol content formula (< 0.03 g/L)
Study: 12187294
Drug: Medium cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium cholesterol content formula (0.15 g/L)
Study: 12187294
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol content formula (0.30 g/L)
Study: 9856918
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg for 5 weeks
Study: 9856918
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg for 10 weeks
Study: 7825521
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (30 mg Fe daily for 8 weeks)
Study: 7825521
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron supplementation (30 mg Fe twice per week for 8 weeks)
Study: 2214868
Drug: IMREG‐1 (immunosupportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMREG‐1 (immunosupportive biological agent derived from human leukocytes)
Study: 89449
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ERCP and direct ductal aspiration for cytology
Study: 23403068
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg/day)
Study: 15812262
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg/day)
Study: 1900483
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist followed by hMG stimulation (group B)
Study: 6618393
Drug: Sportgel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sportgel treatment
Study: 30224319
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg once daily for 16 weeks
Study: 21546942
Drug: Probiotic-supplemented feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-supplemented feeding (Lactobacillus rhamnosus GG and Bifidobacterium infantis added to enteral feeding, continued once daily until discharge or 34 weeks PMA)
Study: 20423755
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose dexamethasone
Study: 20423755
Drug: Daily high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily high-dose prednisolone
Study: 18922117
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by hormonal therapy
Study: 15797962
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and luteinizing hormone releasing hormone analog (LHRHa)
Study: 12206636
Drug: Various dose
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dose fractionation schedules for breast cancer radiotherapy
Study: 12412823
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 1 mg
Study: 8594954
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg fentanyl, sodium thiopental, succinylcholine 1 mg/kg
Study: 8594954
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg fentanyl and propofol (demand-adapted)
Study: 8594954
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg fentanyl and propofol (demand-adapted)
Study: 8594954
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg fentanyl, propofol, succinylcholine 1 mg/kg
Study: 26299229
Drug: Nesiritide treatment
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide treatment
Study: 26299229
Drug: Diuretic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diuretic response (weight loss per 40 mg of furosemide)
Study: 26299229
Drug: Diuretic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diuretic response (good responders)
Study: 26299229
Drug: Diuretic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diuretic response based on urine output per 40 mg of furosemide
Study: 25659828
Drug: Adjunctive zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive zonisamide
Study: 17911992
Drug: Retapamulin ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retapamulin ointment, 1% (twice daily for 5 days)
Study: 17911992
Drug: Sodium fusidate
Normalized name: Sodium fusidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium fusidate ointment, 2% (3 times daily for 7 days)
Study: 9084888
Drug: Rectal suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository containing ozagrel tablet